INTRODUCTION - Effective therapy for glucocorticoid-induced osteoporosis has not been established yet, therefore new therapeutic modalities are still of major interest. PATIENTS AND METHODS - The effect of alphacalcidol (1-α- hydroxy-cholecalciferol) on bone metabolism was studied. 41 women were selected who had been recently given long-term glucocorticoid therapy (5-25 mg prednisone daily) for an underlying disease. After 4 weeks of treatment the patients were randomly enrolled into two groups. In group A (n=21) 0.5- 1.0 μg alphacalcidol and in group B (control; n=20) 500 mg calcium was started daily. Biochemical markers of bone metabolism as well as bone mineral density were followed for one year from the start of the steroid intake. RESULTS - Biochemical markers showed a reduction in bone formation in group B. As a consequence, bone mineral density at the spine and femoral neck was significantly decreased after one year. In patients treated with alphacalcidol (group A), bone mineral density did not decrease in the follow- up period. Biochemical parameters indicated suppressed parathyroid hormone levels and stimulation of bone formation in these patients. CONCLUSION - Based on these results, alphacalcidol treatment appears to be effective in preventing glucocorticoid-induced bone loss by reducing secondary hyperparathyroidism and stimulating bone formation.
|Translated title of the contribution||Reduced bone loss by alphacalcidol in glucocorticoid-induced osteoporosis|
|Number of pages||6|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Dec 1 1996|
ASJC Scopus subject areas